- Trial phase
- Commercialized (LDT launch)
- Time to market
- Already commercially available as a laboratory-developed test (LDT) as of October 20, 2026. A future FDA premarket approval submission is planned but no timeline has been announced.
- Why 4/10
- SimpleScreen Lung was already launched commercially as an LDT on October 20, 2026. There is no upcoming PDUFA or pivotal-readout date scheduled in the next ~12 months; the Breakthrough Device Designation (already granted in August 2026) expedites future FDA review but no filing date has been set. With the launch binary already past, the score reflects a commercial-stage product without a hard near-term catalyst.
SimpleScreen Lung was launched as an LDT on October 20, 2026, so the key binary event has passed. Watch for the company's progress toward FDA premarket submission (expedited by Breakthrough Device Designation), commercial adoption metrics, and payer coverage decisions, which will drive the stock over the coming quarters.
Price Chart
Executive Summary
SimpleScreen Lung is Freenome's blood-based, AI-powered multiomic lung cancer screening test, launched commercially on October 20, 2026 as a laboratory-developed test (LDT). It targets adults ages 50-80 with a heavy smoking history (>=20 pack-years) who are not currently in guideline-recommended screening. In an independent validation cohort, the test demonstrated 85% sensitivity at 50% specificity with a 99.8% negative predictive value. The FDA granted Breakthrough Device Designation in August 2026, which could accelerate a future premarket approval pathway. The launch came shortly after Freenome went public via SPAC (July 2026) and received FDA approval for its colorectal cancer test, SimpleScreen CRC (partnered with Abbott), which drove $183.5M in Q3 2026 revenue. With no imminent FDA decision date for SimpleScreen Lung, the stock's near-term trajectory hinges on commercial adoption of the LDT and progress toward a formal FDA submission.
How It Works
SimpleScreen Lung is a blood test that uses artificial intelligence to analyze multiple biological signals (DNA, proteins, and other molecules) from a standard blood draw to detect early signs of lung cancer. It is designed for people aged 50 to 80 who have a significant smoking history (at least 20 pack-years) and are not already getting regular lung cancer screening. The test looks for patterns in the blood that suggest cancer may be present, without requiring a CT scan or invasive procedure.
Trial Status
SimpleScreen Lung was launched commercially on October 20, 2026 as a laboratory-developed test (LDT) through Freenome's CLIA-certified lab. Clinical validation data was presented at the 2026 AACR Annual Meeting, showing 85% sensitivity and 99.8% negative predictive value in an independent cohort. The FDA granted Breakthrough Device Designation on August 12, 2026, which supports an eventual premarket approval submission, though no submission date has been announced.
The Two-Sided Case
Upcoming Catalysts
- Potential FDA premarket approval (PMA) submission for SimpleScreen Lung (no date announced)
- Commercial adoption metrics and physician uptake of the LDT
- Payer coverage and reimbursement decisions for the lung cancer screening test
- Data updates at medical conferences (e.g., future AACR, ASCO presentations)
Source Filing
The SEC filing that triggered this drug report: